Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Eupatilin attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in diabetic rat kidney

Linxin Xu¹, Guoliang Shi², Yali Xu², Gang Lin², Wuzhou Zhang², Jing Yang¹

¹Department of Endocrinology, The First Hospital of Shanxi Medical University, Taiyuan 030001; ²Department of Endocrinology, Changzhi High-tech Development Zone Central Hospital, Shanxi 046000, China.

For correspondence:- Jing Yang Email: jingyang6@hotmail.com Tel:+8613603512746

Accepted: 16 May 2018 Published: 30 June 2018

Citation: Xu L, Shi G, Xu Y, Lin G, Zhang W, Yang J. Eupatilin attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in diabetic rat kidney. Trop J Pharm Res 2018; 17(6):1055-1060 doi: 10.4314/tjpr.v17i6.11

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the nephro-protective effect of eupatilin in diabetic nephropathic (DN) rats.

Method: Diabetes was induced by intraperitoneal administration of streptozotocin (STZ, 55 mg/kg) and confirmed by fasting blood glucose results, while DN was determined by measuring serum urea and creatinine levels on day 40 after STZ administration. The eupatilin-treated group received eupatilin at 50 and 100 mg/kg, p.o. for 20 days, after which blood levels of some biochemical parameters, glomerulosclerosis index, eosinophilic cast index, and expression of MMP-9 were determined using standard procedures.

Results: Treatment with eupatilin significantly decreased serum levels of glucose, creatinine and urea, and increased creatinine clearance, compared to the negative control group. Moreover, eupatilin attenuated changes in kidney histopathology, and significantly enhanced the expression of MMP-9 in the kidney tissues of the DN rats, relative to negative control group.

Conclusion: These results indicate that eupatilin attenuates renal failure in STZ-induced DN rats by upregulating the expression of MMP-9.

Keywords: Eupatilin, Streptozotocin, Diabetic nephropathy, MMP-9